These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 22753481)

  • 1. Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B.
    Sitia G; Aiolfi R; Di Lucia P; Mainetti M; Fiocchi A; Mingozzi F; Esposito A; Ruggeri ZM; Chisari FV; Iannacone M; Guidotti LG
    Proc Natl Acad Sci U S A; 2012 Aug; 109(32):E2165-72. PubMed ID: 22753481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-platelet therapy in the prevention of hepatitis B virus-associated hepatocellular carcinoma.
    Sitia G; Iannacone M; Guidotti LG
    J Hepatol; 2013 Nov; 59(5):1135-8. PubMed ID: 23742914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelets promote liver immunopathology contributing to hepatitis B virus-mediated hepatocarcinogenesis.
    Sitia G
    Semin Oncol; 2014 Jun; 41(3):402-5. PubMed ID: 25023356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Immune Cells in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma.
    Cho HJ; Cheong JY
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-23 production of liver inflammatory macrophages to damaged hepatocytes promotes hepatocellular carcinoma development after chronic hepatitis B virus infection.
    Zang M; Li Y; He H; Ding H; Chen K; Du J; Chen T; Wu Z; Liu H; Wang D; Cai J; Qu C
    Biochim Biophys Acta Mol Basis Dis; 2018 Dec; 1864(12):3759-3770. PubMed ID: 30292634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic hepatitis B: role of anti-platelet therapy in inflammation control.
    Aiolfi R; Sitia G
    Cell Mol Immunol; 2015 May; 12(3):264-8. PubMed ID: 25578311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelets harness the immune response to drive liver cancer.
    Maini MK; Schurich A
    Proc Natl Acad Sci U S A; 2012 Aug; 109(32):12840-1. PubMed ID: 22826219
    [No Abstract]   [Full Text] [Related]  

  • 8. Hepatocellular carcinoma: could antiplatelet drugs be used to prevent HBV-associated hepatocellular carcinoma?
    Greenhill C
    Nat Rev Gastroenterol Hepatol; 2012 Aug; 9(8):425. PubMed ID: 22801727
    [No Abstract]   [Full Text] [Related]  

  • 9. Immune pathogenesis of hepatocellular carcinoma.
    Nakamoto Y; Guidotti LG; Kuhlen CV; Fowler P; Chisari FV
    J Exp Med; 1998 Jul; 188(2):341-50. PubMed ID: 9670046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma.
    Lim CJ; Lee YH; Pan L; Lai L; Chua C; Wasser M; Lim TKH; Yeong J; Toh HC; Lee SY; Chan CY; Goh BK; Chung A; Heikenwälder M; Ng IO; Chow P; Albani S; Chew V
    Gut; 2019 May; 68(5):916-927. PubMed ID: 29970455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HBV-Induced Immune Imbalance in the Development of HCC.
    Chen Y; Tian Z
    Front Immunol; 2019; 10():2048. PubMed ID: 31507621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiplatelet Therapy is Associated with a Better Prognosis for Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma after Liver Resection.
    Lee PC; Yeh CM; Hu YW; Chen CC; Liu CJ; Su CW; Huo TI; Huang YH; Chao Y; Chen TJ; Lin HC; Wu JC
    Ann Surg Oncol; 2016 Dec; 23(Suppl 5):874-883. PubMed ID: 27541812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-35 Suppresses Interleukin-9-Secreting CD4
    Zhang Q; Yang L; Liu S; Zhang M; Jin Z
    Front Immunol; 2021; 12():645835. PubMed ID: 34177894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection-Related Advanced Hepatocellular Carcinoma: A Literature Review.
    Li B; Yan C; Zhu J; Chen X; Fu Q; Zhang H; Tong Z; Liu L; Zheng Y; Zhao P; Jiang W; Fang W
    Front Immunol; 2020; 11():1037. PubMed ID: 32547550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HBV-specific CD4+ cytotoxic T cells in hepatocellular carcinoma are less cytolytic toward tumor cells and suppress CD8+ T cell-mediated antitumor immunity.
    Meng F; Zhen S; Song B
    APMIS; 2017 Aug; 125(8):743-751. PubMed ID: 28493520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Harnessing CD8
    Yue B; Gao Y; Hu Y; Zhan M; Wu Y; Lu L
    Clin Transl Med; 2024 Jul; 14(7):e1731. PubMed ID: 38935536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The direct and indirect roles of HBV in liver cancer: prospective markers for HCC screening and potential therapeutic targets.
    Ringelhan M; O'Connor T; Protzer U; Heikenwalder M
    J Pathol; 2015 Jan; 235(2):355-67. PubMed ID: 25196558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic effector CD8(+) T-cell dynamics.
    Iannacone M
    Cell Mol Immunol; 2015 May; 12(3):269-72. PubMed ID: 25242274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma.
    Chu CM
    J Gastroenterol Hepatol; 2000 May; 15 Suppl():E25-30. PubMed ID: 10921378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NKT and CD8 lymphocytes mediate suppression of hepatocellular carcinoma growth via tumor antigen-pulsed dendritic cells.
    Shibolet O; Alper R; Zlotogarov L; Thalenfeld B; Engelhardt D; Rabbani E; Ilan Y
    Int J Cancer; 2003 Aug; 106(2):236-43. PubMed ID: 12800200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.